136 related articles for article (PubMed ID: 24745683)
41. Immunohistochemical properties of bone marrow mast cells in systemic mastocytosis: evidence for expression of CD2, CD117/Kit, and bcl-x(L).
Jordan JH; Walchshofer S; Jurecka W; Mosberger I; Sperr WR; Wolff K; Chott A; Bühring HJ; Lechner K; Horny HP; Valent P
Hum Pathol; 2001 May; 32(5):545-52. PubMed ID: 11381374
[TBL] [Abstract][Full Text] [Related]
42. Systemic mastocytosis: current classification and novel therapeutic options.
Barbie DA; Deangelo DJ
Clin Adv Hematol Oncol; 2006 Oct; 4(10):768-75. PubMed ID: 17099633
[TBL] [Abstract][Full Text] [Related]
43. Delineation of patterns of bone marrow mast cell infiltration in systemic mastocytosis: value of CD25, correlation with subvariants of the disease, and separation from mast cell hyperplasia.
Krokowski M; Sotlar K; Krauth MT; Födinger M; Valent P; Horny HP
Am J Clin Pathol; 2005 Oct; 124(4):560-8. PubMed ID: 16146815
[TBL] [Abstract][Full Text] [Related]
44. Pathogenesis, clinical features, and treatment advances in mastocytosis.
Pardanani A; Akin C; Valent P
Best Pract Res Clin Haematol; 2006; 19(3):595-615. PubMed ID: 16781490
[TBL] [Abstract][Full Text] [Related]
45. Mast cells and mastocytosis.
Söderholm JD
Dig Dis; 2009; 27 Suppl 1():129-36. PubMed ID: 20203509
[TBL] [Abstract][Full Text] [Related]
46. Mast cell activation disease: An underappreciated cause of neurologic and psychiatric symptoms and diseases.
Afrin LB; Pöhlau D; Raithel M; Haenisch B; Dumoulin FL; Homann J; Mauer UM; Harzer S; Molderings GJ
Brain Behav Immun; 2015 Nov; 50():314-321. PubMed ID: 26162709
[TBL] [Abstract][Full Text] [Related]
47. Mast cell sarcoma of the scalp: the first sign of undisclosed systemic mastocytosis?
Falleti J; Borgia L; Lalinga AV; De Cecio R; Natella V; Patitucci G; Vita G
Pathol Res Pract; 2012 Nov; 208(11):683-6. PubMed ID: 22963840
[TBL] [Abstract][Full Text] [Related]
48. Circulating KIT D816V mutation-positive non-mast cells in peripheral blood are characteristic of indolent systemic mastocytosis.
Kristensen T; Broesby-Olsen S; Vestergaard H; Bindslev-Jensen C; Møller MB;
Eur J Haematol; 2012 Jul; 89(1):42-6. PubMed ID: 22469616
[TBL] [Abstract][Full Text] [Related]
49. KIT mutations in mastocytosis and their potential as therapeutic targets.
Gotlib J
Immunol Allergy Clin North Am; 2006 Aug; 26(3):575-92. PubMed ID: 16931294
[TBL] [Abstract][Full Text] [Related]
50. Continuous diphenhydramine infusion and imatinib for KIT-D816V-negative mast cell activation syndrome: a case report.
Malik F; Ali N; Jafri SIM; Ghani A; Hamid M; Boigon M; Fidler C
J Med Case Rep; 2017 Apr; 11(1):119. PubMed ID: 28438191
[TBL] [Abstract][Full Text] [Related]
51. Neuroimaging evidence of brain abnormalities in mastocytosis.
Boddaert N; Salvador A; Chandesris MO; Lemaître H; Grévent D; Gauthier C; Naggara O; Georgin-Lavialle S; Moura DS; Munsch F; Jaafari N; Zilbovicius M; Lortholary O; Gaillard R; Hermine O
Transl Psychiatry; 2017 Aug; 7(8):e1197. PubMed ID: 28786975
[TBL] [Abstract][Full Text] [Related]
52. Mastocytosis: mediator-related signs and symptoms.
Castells M; Austen KF
Int Arch Allergy Immunol; 2002 Feb; 127(2):147-52. PubMed ID: 11919427
[TBL] [Abstract][Full Text] [Related]
53. A 6-month follow-up of disability, quality of life, and depressive and anxiety symptoms in pediatric migraine with magnesium prophylaxis.
Kovacevic G; Stevanovic D; Bogicevic D; Nikolic D; Ostojic S; Tadic BV; Nikolic B; Bosiocic I; Ivancevic N; Jovanovic K; Samardzic J; Jancic J
Magnes Res; 2017 Nov; 30(4):133-141. PubMed ID: 29637898
[TBL] [Abstract][Full Text] [Related]
54. A case of neuropathic pain in monoclonal mast cell activation syndrome.
Bay JL; Sedarsky KE; Petersen MM
Ann Allergy Asthma Immunol; 2018 May; 120(5):543-544. PubMed ID: 29481890
[No Abstract] [Full Text] [Related]
55. Histamine levels and cardiovascular responses during splenectomy and splenorenal shunt formation in a patient with systemic mastocytosis.
Smith GB; Gusberg RJ; Jordan RH; Kim B
Anaesthesia; 1987 Aug; 42(8):861-7. PubMed ID: 3661931
[TBL] [Abstract][Full Text] [Related]
56. Cognitive Impairment and Depression in Mastocytosis: A Synthesis of the Literature.
Nicoloro-SantaBarbara J; Majd M; Burdick KE; Dixon V; Giannetti MP
Curr Allergy Asthma Rep; 2024 Feb; 24(2):53-62. PubMed ID: 38294589
[TBL] [Abstract][Full Text] [Related]
57. Chorea: a new manifestation of mastocytosis.
Iriarte LM; Mateu J; Cruz G; Escudero J
J Neurol Neurosurg Psychiatry; 1988 Nov; 51(11):1457-8. PubMed ID: 3236025
[No Abstract] [Full Text] [Related]
58. Understanding mast cells and mastocytosis.
Tharp MD
J Invest Dermatol; 1997 May; 108(5):698-9. PubMed ID: 9129217
[No Abstract] [Full Text] [Related]
59. Cognitive, neuropsychiatric and neurological alterations in mastocytosis: A systematic review.
Sagües-Sesé E; García-Casares N; Álvarez-Twose I
Clin Transl Allergy; 2023 Dec; 13(12):e12319. PubMed ID: 38146805
[TBL] [Abstract][Full Text] [Related]
60. Mastocytosis/vasodilatory shock in a 25-year-old woman.
Walton J
J Emerg Nurs; 1989; 15(4):356-7. PubMed ID: 2668604
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
